Leerink Partners Upgrades ARS Pharmaceuticals Inc (SPRY) to Outperform

March 5, 2024 6:07 AM EST
Get Alerts SPRY Hot Sheet
Price: $7.88 -2.72%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 19 | New: 38
Join SI Premium – FREE

Leerink Partners analyst Roanna Ruiz upgraded ARS Pharmaceuticals Inc (NASDAQ: SPRY) from Market Perform to Outperform with a price target of $18.00 (from $6.00).


For an analyst ratings summary and ratings history on ARS Pharmaceuticals Inc click here. For more ratings news on ARS Pharmaceuticals Inc click here.


Shares of ARS Pharmaceuticals Inc closed at $8.65 yesterday.


You May Also Be Interested In





Related Categories

Analyst PT Change, Upgrades